Compare GSK plc (GSK) vs Trip.com Group Ltd (TCOM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Trip.com Group Ltd — how do they compare? GSK plc trades at $50.62 (market cap $102.60B), while Trip.com Group Ltd trades at $45.86 (market cap $29.10B). The key difference: GSK plc is far larger — about 3.5× Trip.com Group Ltd's market cap, and GSK plc pays the higher dividend (3.57%). Which is the better fit depends on your goals.
| GSK | TCOM | |
|---|---|---|
Market Cap | $102.60B | $29.10B |
Sector | Health | Consumer Cyclical |
52-Week High | $61.18 | $78.96 |
52-Week Low | $38.22 | $39.84 |
Enterprise Value | $123.04B | $21.75B |
Dividend Yield | 3.57% | 0.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $52.16, down 1.51% today, with a bullish technical signal supported by moving averages. The company reported strong Q2 2026 earnings of $1.36 per share, beating estimates, and announced a $2.52 billion cost-saving plan to accelerate drug development. Revenue growth remains steady, with 2025 revenue at $32.67 billion and net income of $5.72 billion, though profit margins have fluctuated in recent years.
Outlook is positive with continued earnings beats and strategic investments, but risks include competitive pressures and regulatory uncertainties. Analyst sentiment is mixed with 31% buy ratings, 55% hold, and 14% sell, reflecting cautious optimism amid execution risks and market volatility.
Trip.com (TCOM) trades at $47.12, up 2.12% today, with a bullish technical signal from moving averages and strong fundamentals including a P/E of 6.89 and net income margin of 48.65%. Recent Q2 2026 earnings guidance missed expectations, and the company accepted a $770 million antitrust penalty in China (Reuters, 2026-07-24), creating near-term uncertainty despite robust revenue growth trends from $20.0B in 2022 to $62.4B in 2025.
The stock offers value with low valuation multiples and high profitability, but regulatory risks and muted Q2 guidance pressure upside. Analyst consensus is bullish with a $59.29 price target (67.44% buy ratings), though institutional selling and antitrust concerns warrant caution for investors seeking exposure to China's travel recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Trip.com Group Ltd
Trip.com is the largest online travel agent in China and is positioned to benefit from the country's rising demand for higher-margin outbound travel as passport penetration is only 12% in China. The company generated about 78% of sales from accommodation reservations and transportation ticketing in 2020. The rest of revenue comes from package tours and corporate travel. Prior to the pandemic in 2019, the company generated 25% of revenue from international business, which is important to its margin expansion. Most of sales come from websites and mobile platforms, while the rest come from call centers. The competes in a crowded OTA industry in China, including Meituan, Alibaba-backed Fliggy, Toncheng, and Qunar. The company was founded in 1999 and listed on the Nasdaq in December 2003.
Read more on TCOM →
